AstraZeneca gains European approval for blood-thinning drug Brilique

6 December 2010

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that the European Commission has granted marketing authorization for its blockbuster potential oral blood thinning drug candidate Brilique (ticagrelor) for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS).

This decision follows the positive opinion from the Committee for Medicinal Products for Human Use (The Pharma Letter September 26) and is applicable to the 27 European Union member states and the three European Economic Area countries of the European Union. Ticagrelor is still under review at the US Food and Drug Administration, which has extended the Prescription Drug User Fee Act (PDUFA) date for approving the drug - to be known as Brilinta in the USA - from September 16 to December 16, 2010.

Annual sales of $2.3 billion forecast

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK